Globally, vaping prevalence among those aged 13 to 15 years is on average nine times that of adults — a disparity that Maddox and colleagues argued should reframe the debate away from individual behavior and toward the commercial systems that make youth uptake predictable.

Writing in PLOS Medicine, Raglan Maddox, PhD, of Australian National University, and colleagues contended that e-cigarettes are not accidentally appealing to adolescents. Flavors, device aesthetics, nicotine salts, digital integration, and misleading labeling work together to increase palatability and accelerate dependence — particularly among people who have not previously used nicotine. In US sales data cited by the authors, the share of e-cigarette products containing at least 5% nicotine strength increased by 1,486% from 2017 to 2022. The authors framed youth uptake as a commercially predictable outcome enabled by product design, market conditions, and regulatory gaps — not as an unintended consequence of otherwise neutral systems.

The deeper argument targets industry messaging. The Perspective takes aim at contemporary "harm reduction" narratives that emphasize personal choice and the inevitability of nicotine use while minimizing the role of product design and commercial systems in producing addiction. The authors described this framing as consistent with long-standing tobacco industry strategies to manufacture doubt and delay regulation. As they wrote: "Youth uptake is not a failure of individual choice or a lack of awareness of harms, but a predictable outcome of an industry structured and incentivised to generate and sustain addiction."

The authors noted growing evidence of harms in youth, including addiction, toxicity through inhalation, poisoning, burns and injuries, lung injury, increased smoking uptake, and concerning cardiovascular, respiratory, and carcinogenic findings, while emphasizing that the long-term effects of e-cigarettes on many clinical outcomes remain uncertain. As a Perspective, the piece is not designed to provide a full risk-benefit analysis of adult cessation utility versus youth initiation risk, and clinicians operating in that space will still find themselves navigating genuine uncertainty.

The institutional takeaway is concrete: pre-market safety standards, retailer licensing reform, flavor restrictions, and full implementation of the WHO Framework Convention on Tobacco Control. For clinicians, the upstream implication is that product design, nicotine delivery, and retail and digital exposure should be recognized as determinants of adolescent nicotine dependence — not just background context for a counseling conversation.

Disclosures: The authors disclosed advisory roles and competitive grant funding from public health, government, nonprofit, and research organizations. They also stated that they have never accepted funding or other support from the tobacco or e-cigarette industries.

Source: PLOS Medicine